ARVN Q2 2025 Earnings — Arvinas, Inc. Revenue & Financial Results | Market Cap Arena

ARVNArvinas, Inc.

$907M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$22M-70.7% YoY

Gross Profit

$22M100.0% margin

Operating Income

-$72M-319.2% margin

Net Income

-$61M-273.2% margin

EPS (Diluted)

$-0.84

QoQ Revenue Growth

-88.1%

Cash Flow

Operating Cash Flow

-$95M

Free Cash Flow

-$97M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$909M

Total Liabilities

$300M

Stockholders' Equity

$609M

Cash & Equivalents

$115M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$22M	$77M	-70.7%
Gross Profit	$22M	$75M	-70.1%
Operating Income	-$72M	-$49M	-47.4%
Net Income	-$61M	-$35M	-73.9%

Revenue Segments

License

$130M100%